UCB:EBR
UCB SA
€296.50
arrow_upward
+0.44%(+1.30) 1D
Nov 13, 5:39:27 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCB...
Open
€294.00
High
€298.00
Low
€294.00
Mkt. cap
57.87B
Avg. vol.
294.41K
Volume
170.43K
Dividend
0.34%
Quarterly dividend
€0.25
Ex-dividend date
May 4, 2026
P/E ratio
26.22
52-wk high
€301.20
52-wk low
€197.45
EPS
€11.31
Shares outstanding
194.51M
No. of employees
9K
Open
€294.00
High
€298.00
Low
€294.00
Mkt. cap
57.87B
Avg. vol.
294.41K
Volume
170.43K
Dividend
0.34%
Quarterly dividend
€0.25
Ex-dividend date
May 4, 2026
P/E ratio
26.22
52-wk high
€301.20
52-wk low
€197.45
EPS
€11.31
Shares outstanding
194.51M
No. of employees
9K
News stories
From web sources and news partners
Reuters
·
17 hours ago
S&P 500, Nasdaq end lower as Nvidia uncertainty weighs on tech shares
marketscreener.com
·
6 hours ago
S&P 500 Posts Weekly Gain as Energy Sector Leads Broad Climb
Investing.com
·
6 hours ago
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.10%
qz.com
·
6 hours ago
How much of the S&P 500 is Nvidia? Concentration explained
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB SA
CEOJean-Christophe Tellier
Employees9K
FoundedJan 18, 1928
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteucb.com